{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:00:33Z","timestamp":1791406833736,"version":"4.3.3"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rising antimicrobial resistance rates may impact the efficacy of empirical antibiotic treatment for febrile neutropenia in high-risk cancer patients. Lacking contemporary data about the epidemiology, antibiotic resistance patterns, and clinical outcomes from bloodstream infections (BSIs) in US cancer patients, it is unclear if current guidelines remain relevant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a cross-sectional study, 14 US cancer centers prospectively identified BSIs in high-risk febrile neutropenic (FN) patients, including those receiving chemotherapy for hematologic malignancies or hematopoietic stem cell transplantation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 389 organisms causing BSI in 343 patients, there was an equal distribution of gram-negative (GN) and gram-positive (GP) bacteria, with variability across centers. Cefepime and piperacillin-tazobactam were the most commonly prescribed empirical antibiotics for FN, at 62% and 23%, respectively; a GP-directed agent was empirically included in nearly half of all FN episodes within the first 24 hours. Susceptibility to fluoroquinolones, cefepime, piperacillin-tazobactam, and carbapenems was 49%, 84%, 88%, and 96%, respectively, among GN isolates. Critical illness (CrI), defined as a new requirement for mechanical ventilation, vasopressor, or death within 30 days, occurred in 15% and did not correlate with fluoroquinolone prophylaxis, organism type, initial antibiotics, or adequacy of coverage. Only severity of illness at presentation, signified by a Pitt bacteremia score \u22652, predicted for critical illness within 30 days. Mortality was 4% by day 7 and 10% overall.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In accordance with US guidelines, cefepime or piperacillin-tazobactam remain effective agents or empirical treatment for high-risk cancer patients with FN who are stable at presentation, maintaining high GN pathogen susceptibility and yielding excellent outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofac240","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T04:46:37Z","timestamp":1652849197000},"source":"Crossref","is-referenced-by-count":44,"title":["Bloodstream Infections in Hematologic Malignancy Patients With Fever and Neutropenia: Are Empirical Antibiotic Therapies in the United States Still Effective?"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1460-0774","authenticated-orcid":false,"given":"Andrea J","family":"Zimmer","sequence":"first","affiliation":[{"name":"University of Nebraska College of Medicine , Omaha, Nebraska , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Stohs","sequence":"additional","affiliation":[{"name":"University of Nebraska College of Medicine , Omaha, Nebraska , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Meza","sequence":"additional","affiliation":[{"name":"University of Nebraska College of Public Health , Omaha, Nebraska , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Arnold","sequence":"additional","affiliation":[{"name":"University of Virginia , Charlottesville, Virginia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9111-625X","authenticated-orcid":false,"given":"John W","family":"Baddley","sequence":"additional","affiliation":[{"name":"University of Maryland , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranatharthi","family":"Chandrasekar","sequence":"additional","affiliation":[{"name":"Wayne State University , Detroit, Michigan , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab","family":"El Boghdadly","sequence":"additional","affiliation":[{"name":"Ohio State University Wexner Medical Center , Columbus, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A","family":"Gomez","sequence":"additional","affiliation":[{"name":"University of Utah School of Medicine , Salt Lake City, Utah , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen K","family":"Maziarz","sequence":"additional","affiliation":[{"name":"Duke University Medical Center , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose G","family":"Montoya","sequence":"additional","affiliation":[{"name":"The Dr. Jack S. Remington Laboratory for Specialty Diagnostics at the Palo Alto Medical Foundation , Palo Alto, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Pergam","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth V","family":"Rolston","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Satlin","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine of Cornell University , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gowri","family":"Satyanarayana","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center , Nashville, Tennessee , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shmuel","family":"Shoham","sequence":"additional","affiliation":[{"name":"Johns Hopkins University , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Strasfeld","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University , Portland, Oregon , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy","family":"Taplitz","sequence":"additional","affiliation":[{"name":"COH National Medical Center , Duarte, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J","family":"Walsh","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine of Cornell University , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo-Anne H","family":"Young","sequence":"additional","affiliation":[{"name":"University of Minnesota , Minneapolis, Minnesota , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuning","family":"Zhang","sequence":"additional","affiliation":[{"name":"University of Nebraska College of Medicine , Omaha, Nebraska , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison G","family":"Freifeld","sequence":"additional","affiliation":[{"name":"University of Nebraska College of Medicine , Omaha, Nebraska , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"2022073010001097400_ofac240-B1","doi-asserted-by":"crossref","first-page":"e56\u2013","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2022073010001097400_ofac240-B2","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1002\/cncr.25691","article-title":"Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy","volume":"117","author":"Lyman","year":"2011","journal-title":"Cancer"},{"key":"2022073010001097400_ofac240-B3","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"key":"2022073010001097400_ofac240-B4","doi-asserted-by":"crossref","first-page":"328","DOI":"10.7326\/0003-4819-64-2-328","article-title":"Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia","volume":"64","author":"Bodey","year":"1966","journal-title":"Ann Intern Med"},{"key":"2022073010001097400_ofac240-B5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1001\/jama.1965.03090020019005","article-title":"Causes of death in acute leukemia: a ten-year study of 414 patients from 1954-1963","volume":"193","author":"Hersh","year":"1965","journal-title":"JAMA"},{"issue":"Suppl 1","key":"2022073010001097400_ofac240-B6","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.ijantimicag.2007.06.012","article-title":"Bacteraemia in febrile neutropenic cancer patients","volume":"30","author":"Klastersky","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"2022073010001097400_ofac240-B7","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"key":"2022073010001097400_ofac240-B8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.critrevonc.2010.03.008","article-title":"Febrile neutropenia: a critical review of the initial management","volume":"78","author":"Klastersky","year":"2011","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"2022073010001097400_ofac240-B9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.cmi.2014.11.022","article-title":"Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey","volume":"21","author":"Trecarichi","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2022073010001097400_ofac240-B10","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3324\/haematol.2013.091025","article-title":"European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia","volume":"98","author":"Averbuch","year":"2013","journal-title":"Haematologica"},{"key":"2022073010001097400_ofac240-B11","doi-asserted-by":"crossref","first-page":"882","DOI":"10.6004\/jnccn.2016.0093","article-title":"Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology","volume":"14","author":"Baden","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"2022073010001097400_ofac240-B12","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1086\/322604","article-title":"Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients","volume":"33","author":"Collin","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2022073010001097400_ofac240-B13","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1086\/374339","article-title":"Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States","volume":"36","author":"Wisplinghoff","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2022073010001097400_ofac240-B14","first-page":"1068","article-title":"Inappropriate empirical antibiotic treatment in high-risk neutropenic patients with bacteremia in the era of multidrug resistance","volume":"70","author":"Martinez-Nadal","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022073010001097400_ofac240-B15","doi-asserted-by":"crossref","first-page":"e0199531","DOI":"10.1371\/journal.pone.0199531","article-title":"Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance","volume":"13","author":"Garcia-Vidal","year":"2018","journal-title":"PLoS One"},{"key":"2022073010001097400_ofac240-B16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1159\/000329661","article-title":"Incidence of fluoroquinolone-resistant and extended-spectrum \u03b2-lactamase-producing Escherichia coli at a comprehensive cancer center in the United States","volume":"57","author":"Bhusal","year":"2011","journal-title":"Chemotherapy"},{"key":"2022073010001097400_ofac240-B17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbmt.2008.10.024","article-title":"Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of gram-negative rods and increasing antibiotic resistance","volume":"15","author":"Mikulska","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"2022073010001097400_ofac240-B18","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research Electronic Data Capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2022073010001097400_ofac240-B19","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s15010-019-01277-7","article-title":"Derivation of a quick Pitt bacteremia score to predict mortality in patients with gram-negative bloodstream infection","volume":"47","author":"Battle","year":"2019","journal-title":"Infection"},{"key":"2022073010001097400_ofac240-B20","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/cid\/ciz528","article-title":"The Pitt bacteremia score predicts mortality in nonbacteremic infections","volume":"70","author":"Henderson","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022073010001097400_ofac240-B21","article-title":"Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. Clinical and Laboratory Standards Institute","author":"Clinical and Laboratory Standards Institute","year":"2020"},{"key":"2022073010001097400_ofac240-B22","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1038\/s41409-020-0811-y","article-title":"Current antimicrobial practice in febrile neutropenia across Europe and Asia: the EBMT Infectious Disease Working Party survey","volume":"55","author":"Verlinden","year":"2020","journal-title":"Bone Marrow Transplantation"},{"key":"2022073010001097400_ofac240-B23","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/cid\/cix646","article-title":"Antimicrobial resistance in gram-negative rods causing bacteremia in hematopoietic stem cell transplant recipients: intercontinental prospective study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group","volume":"65","author":"Averbuch","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2022073010001097400_ofac240-B24","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1086\/655132","article-title":"Cefepime and death: reality to the rescue","volume":"51","author":"Freifeld","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2022073010001097400_ofac240-B25","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/655131","article-title":"Meta-analysis of a possible signal of increased mortality associated with cefepime use","volume":"51","author":"Kim","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2022073010001097400_ofac240-B26","article-title":"The dose-dependent efficacy of cefepime in the empiric management of febrile neutropenia: a systematic review and meta-analysis","volume":"4:XXX\u2013XX","author":"Andreatos","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2022073010001097400_ofac240-B27","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00134-014-3374-9","article-title":"Neutropenic cancer patients with severe sepsis: need for antibiotics in the first hour","volume":"40","author":"Mokart","year":"2014","journal-title":"Intensive Care Med"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofac240\/43746883\/ofac240.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/7\/ofac240\/45028939\/ofac240.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/7\/ofac240\/45028939\/ofac240.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T06:02:20Z","timestamp":1659160940000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofac240\/6587378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofac240","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,5,18]]},"article-number":"ofac240"}}